Smith & Nephew logo

Smith & NephewNYSE: SNN

Profile

Sector:

Healthcare

Country:

United Kingdom

IPO:

16 November 1999

Next earnings report:

27 February 2025

Last dividends:

04 October 2024

Next dividends:

N/A
$10.99 B
-31%vs. 3y high
93%vs. sector
-vs. 3y high
-vs. sector
-26%vs. 3y high
59%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 21:05:02 GMT
$25.21-$0.30(-1.18%)
No data over the past 3 years
$1.54 B$1.41 B
No data over the past 3 years

Analysts recommendations

Institutional Ownership

SNN Latest News

Big investors call for break-up of Smith & Nephew, FT reports
reuters.com14 November 2024 Sentiment: NEGATIVE

Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders.

Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends
seekingalpha.com10 November 2024 Sentiment: POSITIVE

Smith & Nephew's Q3 results led to a 13% share price drop due to reduced FY24 guidance, mainly from lower demand in China. Despite short-term challenges, long-term fundamentals remain strong, presenting a buying opportunity at current lower prices. The company's 12-point plan aims to boost growth and margins, focusing on orthopedics, productivity, and accelerating growth in advanced wound management and sports medicine.

Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript
seekingalpha.com02 November 2024 Sentiment: POSITIVE

Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Management David Adlington - J.P. Morgan Hassan Al-Wakeel - Barclays Robert Davies - Morgan Stanley Richard Felton - Goldman Sachs Graham Doyle - UBS Lisa Clive - Bernstein Julien Dormois - Jefferies Deepak Nath Good morning, and welcome to the Smith & Nephew third quarter trading update.

Smith & Nephew slashes annual revenue forecast on weak China
reuters.com31 October 2024 Sentiment: NEGATIVE

British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its surgical businesses in China.

SNN Stock May Gain Following the Co-Marketing Deal With JointVue
zacks.com15 October 2024 Sentiment: POSITIVE

Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.

SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
zacks.com11 October 2024 Sentiment: POSITIVE

Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation.

Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery
globenewswire.com09 October 2024 Sentiment: POSITIVE

Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-marketing agreement with JointVue for its patented OrthoSonic™ 3D Surgery Planning Technology – the only ultrasound device currently on the market to deliver 3D preoperative planning. JointVue's technology allows surgeons using Smith+Nephew's CORI◊ Surgical System for robotic-assisted knee arthroplasty to create a personalized surgical plan, which may provide opportunities to improve patient satisfaction and operating room efficiency.

SNN Stock Rises on the Completion of First Case With CATALYSTEM System
zacks.com20 September 2024 Sentiment: POSITIVE

Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System.

First cases using Smith+Nephew's new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
globenewswire.com18 September 2024 Sentiment: POSITIVE

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures – the CATALYSTEM Primary Hip System features a triple-taper stem design with uniform proximal loading.1  The reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches.2

SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
zacks.com13 September 2024 Sentiment: NEUTRAL

Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.

  • 1(current)
  • 2
  • 3

What type of business is Smith & Nephew?

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

What sector is Smith & Nephew in?

Smith & Nephew is in the Healthcare sector

What industry is Smith & Nephew in?

Smith & Nephew is in the Medical Devices industry

What country is Smith & Nephew from?

Smith & Nephew is headquartered in United Kingdom

When did Smith & Nephew go public?

Smith & Nephew initial public offering (IPO) was on 16 November 1999

What is Smith & Nephew website?

https://www.smith-nephew.com

Is Smith & Nephew in the S&P 500?

No, Smith & Nephew is not included in the S&P 500 index

Is Smith & Nephew in the NASDAQ 100?

No, Smith & Nephew is not included in the NASDAQ 100 index

Is Smith & Nephew in the Dow Jones?

No, Smith & Nephew is not included in the Dow Jones index

When was Smith & Nephew the previous earnings report?

No data

When does Smith & Nephew earnings report?

The next expected earnings date for Smith & Nephew is 27 February 2025